Top

Published in:

Open Access 01-02-2021 | Acute Myeloid Leukemia | Original Article

Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125

Authors: Yu-Hung Wang, Chien-Chin Lin, Chia-Lang Hsu, Sheng-Yu Hung, Chi-Yuan Yao, Sze-Hwei Lee, Cheng-Hong Tsai, Hsin-An Hou, Wen-Chien Chou, Hwei-Fang Tien

Published in: Annals of Hematology | Issue 2/2021

Abstract

Expression of long non-coding RNA KIAA0125 has been incorporated in various gene expression signatures for prognostic prediction in acute myeloid leukemia (AML) patients, yet its functions and clinical significance remain unclear. This study aimed to investigate the clinical and biological characteristics of AML bearing different levels of KIAA0125. We profiled KIAA0125 expression levels in bone marrow cells from 347 de novo AML patients and found higher KIAA0125 expression was closely associated with RUNX1 mutation, but inversely correlated with t(8;21) and t(15;17) karyotypes. Among the 227 patients who received standard chemotherapy, those with higher KIAA0125 expression had a lower complete remission rate, shorter overall survival (OS) and disease-free survival (DFS) than those with lower expression. The prognostic significance was validated in both TCGA and GSE12417 cohorts. Subgroup analyses showed that higher KIAA0125 expression also predicted shorter DFS and OS in patients with normal karyotype or non-M3 AML. In multivariable analysis, higher KIAA0125 expression remained an adverse risk factor independent of age, WBC counts, karyotypes, and mutation patterns. Bioinformatics analyses revealed that higher KIAA0125 expression was associated with hematopoietic and leukemic stem cell signatures and ATP-binding cassette transporters, two predisposing factors for chemoresistance.

Available only for authorised users

Fatica A, Bozzoni I (2014) Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet 15(1):7–21. https://doi.org/10.1038/nrg3606CrossRefPubMed

Wilusz JE, Sunwoo H, Spector DL (2009) Long noncoding RNAs: functional surprises from the RNA world. Genes Dev 23(13):1494–1504. https://doi.org/10.1101/gad.1800909CrossRefPubMedPubMedCentral

Kung JT, Colognori D, Lee JT (2013) Long noncoding RNAs: past, present, and future. Genetics 193(3):651–669. https://doi.org/10.1534/genetics.112.146704CrossRefPubMedPubMedCentral

Mercer TR, Dinger ME, Mattick JS (2009) Long non-coding RNAs: insights into functions. Nat Rev Genet 10(3):155–159. https://doi.org/10.1038/nrg2521CrossRefPubMed

Lin C, Yang L (2018) Long noncoding RNA in Cancer: wiring signaling circuitry. Trends Cell Biol 28(4):287–301. https://doi.org/10.1016/j.tcb.2017.11.008CrossRefPubMed

Prensner JR, Chinnaiyan AM (2011) The emergence of lncRNAs in cancer biology. Cancer discovery 1(5):391–407. https://doi.org/10.1158/2159-8290.Cd-11-0209CrossRefPubMedPubMedCentral

Huarte M (2015) The emerging role of lncRNAs in cancer. Nat Med 21(11):1253–1261. https://doi.org/10.1038/nm.3981CrossRefPubMed

Cheetham SW, Gruhl F, Mattick JS, Dinger ME (2013) Long noncoding RNAs and the genetics of cancer. Br J Cancer 108(12):2419–2425. https://doi.org/10.1038/bjc.2013.233CrossRefPubMedPubMedCentral

Alvarez-Dominguez JR, Lodish HF (2017) Emerging mechanisms of long noncoding RNA function during normal and malignant hematopoiesis. Blood 130(18):1965–1975. https://doi.org/10.1182/blood-2017-06-788695CrossRefPubMedPubMedCentral

10.

De Clara E, Gourvest M, Ma H, Vergez F, Tosolini M, Dejean S et al (2017) Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients. Haematologica 102(10):1718–1726. https://doi.org/10.3324/haematol.2017.171645CrossRefPubMedPubMedCentral

11.

Papaioannou D, Nicolet D, Volinia S, Mrózek K, Yan P, Bundschuh R, Carroll AJ, Kohlschmidt J, Blum W, Powell BL, Uy GL, Kolitz JE, Wang ES, Eisfeld AK, Orwick SJ, Lucas DM, Caligiuri MA, Stone RM, Byrd JC, Garzon R, Bloomfield CD (2017) Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. Haematologica 102(8):1391–1400. https://doi.org/10.3324/haematol.2017.166215CrossRefPubMedPubMedCentral

12.

Schwarzer A, Emmrich S, Schmidt F, Beck D, Ng M, Reimer C, Adams FF, Grasedieck S, Witte D, Käbler S, Wong JWH, Shah A, Huang Y, Jammal R, Maroz A, Jongen-Lavrencic M, Schambach A, Kuchenbauer F, Pimanda JE, Reinhardt D, Heckl D, Klusmann JH (2017) The non-coding RNA landscape of human hematopoiesis and leukemia. Nat Commun 8(1):218. https://doi.org/10.1038/s41467-017-00212-4CrossRefPubMedPubMedCentral

13.

Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrózek K, Bucci D, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Moore JO, Eisfeld AK, Blachly JS, Blum W, Caligiuri MA, Stone RM, Marcucci G, Croce CM, Byrd JC, Bloomfield CD (2014) Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proc Natl Acad Sci U S A 111(52):18679–18684. https://doi.org/10.1073/pnas.1422050112CrossRefPubMedPubMedCentral

14.

Smith JL, Ries RE, Farrar JE, Alonzo TA, Gerbing RB, Leonti AR et al (2019) Long non-coding RNAs (lncRNAs) are highly associated with disease characteristics and outcome in pediatric acute myeloid leukemia - a COG and Tpaml study. Blood 134(Supplement_1):2741. https://doi.org/10.1182/blood-2019-127318CrossRef

15.

Pashaiefar H, Izadifard M, Yaghmaie M, Montazeri M, Gheisari E, Ahmadvand M, Momeny M, Ghaffari SH, Kasaeian A, Alimoghaddam K, Ghavamzadeh A (2018) Low expression of long noncoding RNA IRAIN is associated with poor prognosis in non-M3 acute myeloid leukemia patients. Genet Test Mol Biomarkers 22(5):288–294. https://doi.org/10.1089/gtmb.2017.0281CrossRefPubMed

16.

Fernando TR, Contreras JR, Zampini M, Rodriguez-Malave NI, Alberti MO, Anguiano J, Tran TM, Palanichamy JK, Gajeton J, Ung NM, Aros CJ, Waters EV, Casero D, Basso G, Pigazzi M, Rao DS (2017) The lncRNA CASC15 regulates SOX4 expression in RUNX1-rearranged acute leukemia. Mol Cancer 16(1):126. https://doi.org/10.1186/s12943-017-0692-xCrossRefPubMedPubMedCentral

17.

Salehi M, Sharifi M, Bagheri M (2019) Knockdown of long noncoding RNA Plasmacytoma variant translocation 1 with antisense locked nucleic acid GapmeRs exerts tumor-suppressive functions in human acute Erythroleukemia cells through Downregulation of C-MYC expression. Cancer Biother Radiopharm 34(6):371–379. https://doi.org/10.1089/cbr.2018.2510CrossRefPubMed

18.

El-Khazragy N, Elayat W, Matbouly S, Seliman S, Sami A, Safwat G et al (2019) The prognostic significance of the long non-coding RNAs "CCAT1, PVT1" in t(8;21) associated acute myeloid leukemia. Gene 707:172–177. https://doi.org/10.1016/j.gene.2019.03.055CrossRefPubMed

19.

Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N et al (2016) A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 540(7633):433–437. https://doi.org/10.1038/nature20598CrossRefPubMed

20.

Metzeler KH, Hummel M, Bloomfield CD, Spiekermann K, Braess J, Sauerland MC, Heinecke A, Radmacher M, Marcucci G, Whitman SP, Maharry K, Paschka P, Larson RA, Berdel WE, Büchner T, Wörmann B, Mansmann U, Hiddemann W, Bohlander SK, Buske C, Cancer and Leukemia Group B, German AML Cooperative Group (2008) An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 112(10):4193–4201. https://doi.org/10.1182/blood-2008-02-134411CrossRefPubMedPubMedCentral

21.

Chuang MK, Chiu YC, Chou WC, Hou HA, Tseng MH, Kuo YY et al (2015) An mRNA expression signature for prognostication in de novo acute myeloid leukemia patients with normal karyotype. Oncotarget 6(36):39098–39110. https://doi.org/10.18632/oncotarget.5390CrossRefPubMedPubMedCentral

22.

Wilop S, Chou WC, Jost E, Crysandt M, Panse J, Chuang MK, Brümmendorf TH, Wagner W, Tien HF, Kharabi Masouleh B (2016) A three-gene expression-based risk score can refine the European LeukemiaNet AML classification. J Hematol Oncol 9(1):78. https://doi.org/10.1186/s13045-016-0308-8CrossRefPubMedPubMedCentral

23.

Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, Kohlschmidt J, Mrózek K, Wu YZ, Bucci D, Curfman JP, Whitman SP, Eisfeld AK, Mendler JH, Schwind S, Becker H, Bär C, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Byrd JC, Plass C, Garzon R, Caligiuri MA, Stone RM, Volinia S, Bundschuh R, Bloomfield CD (2014) Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol 32(6):548–556. https://doi.org/10.1200/jco.2013.50.6337CrossRefPubMed

24.

Li Z, Herold T, He C, Valk PJ, Chen P, Jurinovic V et al (2013) Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol 31(9):1172–1181. https://doi.org/10.1200/JCO.2012.44.3184CrossRefPubMedPubMedCentral

25.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405. https://doi.org/10.1182/blood-2016-03-643544CrossRefPubMed

26.

Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33(4):451–458. https://doi.org/10.1111/j.1365-2141.1976.tb03563.xCrossRefPubMed

27.

Tang JL, Hou HA, Chen CY, Liu CY, Chou WC, Tseng MH, Huang CF, Lee FY, Liu MC, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Lin LI, Tien HF (2009) AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 114(26):5352–5361CrossRefPubMed

28.

Chiu YC, Tsai MH, Chou WC, Liu YC, Kuo YY, Hou HA, Lu TP, Lai LC, Chen Y, Tien HF, Chuang EY (2016) Prognostic significance of NPM1 mutation-modulated microRNA-mRNA regulation in acute myeloid leukemia. Leukemia 30(2):274–284. https://doi.org/10.1038/leu.2015.253CrossRefPubMed

29.

Chuang MK, Chiu YC, Chou WC, Hou HA, Chuang EY, Tien HF (2015) A 3-microRNA scoring system for prognostication in de novo acute myeloid leukemia patients. Leukemia 29(5):1051–1059. https://doi.org/10.1038/leu.2014.333CrossRefPubMed

30.

Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A et al (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368(22):2059–2074. https://doi.org/10.1056/NEJMoa1301689CrossRefPubMed

31.

Chou WC, Chou SC, Liu CY, Chen CY, Hou HA, Kuo YY, Lee MC, Ko BS, Tang JL, Yao M, Tsay W, Wu SJ, Huang SY, Hsu SC, Chen YC, Chang YC, Kuo YY, Kuo KT, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF, Tien HF (2011) TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics. Blood 118(14):3803–3810. https://doi.org/10.1182/blood-2011-02-339747CrossRefPubMed

32.

Chou WC, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, Ko BS, Wu SJ, Huang SY, Hsu SC, Chen YC, Huang YN, Chang YC, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF, Tien HF (2010) Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 115(14):2749–2754. https://doi.org/10.1182/blood-2009-11-253070CrossRefPubMed

33.

Chou WC, Huang HH, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, Ko BS, Wu SJ, Huang SY, Hsu SC, Chen YC, Huang YN, Chang YC, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF, Tien HF (2010) Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood 116(20):4086–4094. https://doi.org/10.1182/blood-2010-05-283291CrossRefPubMed

34.

Hou HA, Lin CC, Chou WC, Liu CY, Chen CY, Tang JL, Lai YJ, Tseng MH, Huang CF, Chiang YC, Lee FY, Kuo YY, Lee MC, Liu MC, Liu CW, Lin LI, Yao M, Huang SY, Ko BS, Hsu SC, Wu SJ, Tsay W, Chen YC, Tien HF (2014) Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia 28(1):50–58. https://doi.org/10.1038/leu.2013.236CrossRefPubMed

35.

Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK, on behalf of the National Cancer Research Institute Adult Leukaemia Working Group (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116(3):354–365. https://doi.org/10.1182/blood-2009-11-254441CrossRefPubMed

36.

Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, Metzeler KH, Poeppl A, Ling V, Beyene J, Canty AJ, Danska JS, Bohlander SK, Buske C, Minden MD, Golub TR, Jurisica I, Ebert BL, Dick JE (2011) Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 17(9):1086–1093. https://doi.org/10.1038/nm.2415CrossRefPubMed

37.

Ivanova NB, Dimos JT, Schaniel C, Hackney JA, Moore KA, Lemischka IR (2002) A stem cell molecular signature. Science 298(5593):601–604. https://doi.org/10.1126/science.1073823CrossRefPubMed

38.

Jaatinen T, Hemmoranta H, Hautaniemi S, Niemi J, Nicorici D, Laine J, Yli-Harja O, Partanen J (2006) Global gene expression profile of human cord blood-derived CD133+ cells. Stem Cells 24(3):631–641. https://doi.org/10.1634/stemcells.2005-0185CrossRefPubMed

39.

Xue C, Zhang J, Zhang G, Xue Y, Zhang G, Wu X (2019) Elevated SPINK2 gene expression is a predictor of poor prognosis in acute myeloid leukemia. Oncol Lett 18(3):2877–2884. https://doi.org/10.3892/ol.2019.10665CrossRefPubMedPubMedCentral

40.

Elsayed AH, Rafiee R, Cao X, Raimondi S, Downing JR, Ribeiro R, Fan Y, Gruber TA, Baker S, Klco J, Rubnitz JE, Pounds S, Lamba JK (2020) A six-gene leukemic stem cell score identifies high risk pediatric acute myeloid leukemia. Leukemia 34(3):735–745. https://doi.org/10.1038/s41375-019-0604-8CrossRefPubMed

41.

Fu L, Fu H, Zhou L, Xu K, Pang Y, Hu K, Wang J, Tian L, Liu Y, Wang J, Jing H, Huang W, Ke X, Shi J (2016) High expression of MAP7 predicts adverse prognosis in young patients with cytogenetically normal acute myeloid leukemia. Sci Rep 6:34546. https://doi.org/10.1038/srep34546CrossRefPubMedPubMedCentral

42.

Lin CC, Hsu YC, Li YH, Kuo YY, Hou HA, Lan KH, Chen TC, Tzeng YS, Kuo YY, Kao CJ, Chuang PH, Tseng MH, Chiu YC, Chou WC, Tien HF (2017) Higher HOPX expression is associated with distinct clinical and biological features and predicts poor prognosis in de novo acute myeloid leukemia. Haematologica 102(6):1044–1053. https://doi.org/10.3324/haematol.2016.161257CrossRefPubMedPubMedCentral

43.

Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB (2015) Multimerin-1 (MMRN1) as novel adverse marker in pediatric acute myeloid leukemia: a report from the Children’s oncology group. Clin Cancer Res 21(14):3187–3195. https://doi.org/10.1158/1078-0432.Ccr-14-2684CrossRefPubMedPubMedCentral

44.

Hayette S, Thomas X, Jallades L, Chabane K, Charlot C, Tigaud I, Gazzo S, Morisset S, Cornillet-Lefebvre P, Plesa A, Huet S, Renneville A, Salles G, Nicolini FE, Magaud JP, Michallet M (2012) High DNA methyltransferase DNMT3B levels: a poor prognostic marker in acute myeloid leukemia. PLoS One 7(12):e51527. https://doi.org/10.1371/journal.pone.0051527CrossRefPubMedPubMedCentral

45.

Niederwieser C, Kohlschmidt J, Volinia S, Whitman SP, Metzeler KH, Eisfeld AK, Maharry K, Yan P, Frankhouser D, Becker H, Schwind S, Carroll AJ, Nicolet D, Mendler JH, Curfman JP, Wu YZ, Baer MR, Powell BL, Kolitz JE, Moore JO, Carter TH, Bundschuh R, Larson RA, Stone RM, Mrózek K, Marcucci G, Bloomfield CD (2015) Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemia. Leukemia 29(3):567–575. https://doi.org/10.1038/leu.2014.267CrossRefPubMed

46.

Wong KK, Lawrie CH, Green TM (2019) Oncogenic roles and inhibitors of DNMT1, DNMT3A, and DNMT3B in acute myeloid Leukaemia. Biomark Insights 14:1177271919846454. https://doi.org/10.1177/1177271919846454CrossRefPubMedPubMedCentral

47.

Gerritsen M, Yi G, Tijchon E, Kuster J, Schuringa JJ, Martens JHA, Vellenga E (2019) RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs. Blood Adv 3(3):320–332. https://doi.org/10.1182/bloodadvances.2018024422CrossRefPubMedPubMedCentral

48.

In't Hout FEM, Gerritsen M, Bullinger L, van der Reijden BA, Huls G, Vellenga E et al (2019) Transcription factor 4 (TCF4) expression predicts clinical outcome in RUNX1 mutated and translocated acute myeloid leukemia. Haematologica. 105:e454–e457. https://doi.org/10.3324/haematol.2019.232827CrossRef

49.

Li Y, Shao H, Da Z, Pan J, Fu B (2019) High expression of SLC38A1 predicts poor prognosis in patients with de novo acute myeloid leukemia. J Cell Physiol 234(11):20322–20328. https://doi.org/10.1002/jcp.28632CrossRefPubMed

50.

Lee SH, Chiu YC, Li YH, Lin CC, Hou HA, Chou WC et al (2017) High expression of dedicator of cytokinesis 1 (DOCK1) confers poor prognosis in acute myeloid leukemia. Oncotarget 8(42):72250–72259. https://doi.org/10.18632/oncotarget.19706CrossRefPubMedPubMedCentral

51.

Heuser M, Argiropoulos B, Kuchenbauer F, Yung E, Piper J, Fung S, Schlenk RF, Dohner K, Hinrichsen T, Rudolph C, Schambach A, Baum C, Schlegelberger B, Dohner H, Ganser A, Humphries RK (2007) MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood 110(5):1639–1647. https://doi.org/10.1182/blood-2007-03-080523CrossRefPubMed

52.

Heuser M, Yun H, Berg T, Yung E, Argiropoulos B, Kuchenbauer F, Park G, Hamwi I, Palmqvist L, Lai CK, Leung M, Lin G, Chaturvedi A, Thakur BK, Iwasaki M, Bilenky M, Thiessen N, Robertson G, Hirst M, Kent D, Wilson NK, Göttgens B, Eaves C, Cleary ML, Marra M, Ganser A, Humphries RK (2011) Cell of origin in AML: susceptibility to MN1-induced transformation is regulated by the MEIS1/AbdB-like HOX protein complex. Cancer Cell 20(1):39–52. https://doi.org/10.1016/j.ccr.2011.06.020CrossRefPubMedPubMedCentral

53.

Choi YH, Yu AM (2014) ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des 20(5):793–807. https://doi.org/10.2174/138161282005140214165212CrossRefPubMedPubMedCentral

54.

Dean M (2005) The genetics of ATP-binding cassette transporters. Methods Enzymol 400:409–429. https://doi.org/10.1016/s0076-6879(05)00024-8CrossRefPubMed

55.

Efferth T, Gillet JP, Sauerbrey A, Zintl F, Bertholet V, de Longueville F, Remacle J, Steinbach D (2006) Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia. Mol Cancer Ther 5(8):1986–1994. https://doi.org/10.1158/1535-7163.Mct-06-0086CrossRefPubMed

56.

Marzac C, Garrido E, Tang R, Fava F, Hirsch P, De Benedictis C et al (2011) ATP binding cassette transporters associated with chemoresistance: transcriptional profiling in extreme cohorts and their prognostic impact in a cohort of 281 acute myeloid leukemia patients. Haematologica 96(9):1293–1301. https://doi.org/10.3324/haematol.2010.031823CrossRefPubMedPubMedCentral

57.

Vasiliou V, Vasiliou K, Nebert DW (2009) Human ATP-binding cassette (ABC) transporter family. Hum Genomics 3(3):281–290. https://doi.org/10.1186/1479-7364-3-3-281CrossRefPubMedPubMedCentral

58.

Aberuyi N, Rahgozar S, Khosravi Dehaghi Z, Moafi A, Masotti A, Paolini A (2017) The translational expression of ABCA2 and ABCA3 is a strong prognostic biomarker for multidrug resistance in pediatric acute lymphoblastic leukemia. Onco Targets Ther 10:3373–3380. https://doi.org/10.2147/ott.S140488CrossRefPubMedPubMedCentral

59.

Diniz MG, Franca JA, Vilas-Boas FAS, de Souza FTA, Calin GA, Gomez RS et al (2019) The long noncoding RNA KIAA0125 is upregulated in ameloblastomas. Pathol Res Pract 215(3):466–469. https://doi.org/10.1016/j.prp.2018.12.030CrossRefPubMed

60.

Yang Y, Zhao Y, Hu N, Zhao J, Bai Y (2019) lncRNA KIAA0125 functions as a tumor suppressor modulating growth and metastasis of colorectal cancer via Wnt/beta-catenin pathway. Cell Biol Int 43:1463–1470. https://doi.org/10.1002/cbin.11196CrossRefPubMedCentral

61.

Hornung R, Jurinovic V, Batcha AMN, Bamopoulos SA, Rothenberg-Thurley M, Amler S, Sauerland MC, Berdel WE, Wörmann BJ, Bohlander SK, Braess J, Hiddemann W, Lehmann S, Mareschal S, Spiekermann K, Metzeler KH, Herold T, Boulesteix AL (2018) Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia. Sci Rep 8(1):11293. https://doi.org/10.1038/s41598-018-29593-2CrossRefPubMedPubMedCentral

62.

Bowers SR, Calero-Nieto FJ, Valeaux S, Fernandez-Fuentes N, Cockerill PN (2010) Runx1 binds as a dimeric complex to overlapping Runx1 sites within a palindromic element in the human GM-CSF enhancer. Nucleic Acids Res 38(18):6124–6134. https://doi.org/10.1093/nar/gkq356CrossRefPubMedPubMedCentral

63.

Lin C-C, Yao C-Y, Hsu Y-C, Hou H-A, Yuan C-T, Li Y-H, Kao CJ, Chuang PH, Chiu YC, Chen Y, Chou WC, Tien HF (2020) Knock-out of Hopx disrupts stemness and quiescence of hematopoietic stem cells in mice. Oncogene 39(28):5112–5123. https://doi.org/10.1038/s41388-020-1340-2CrossRefPubMed

Title: Distinct clinical and biological characteristics of acute myeloid leukemia with higher expression of long noncoding RNA KIAA0125
Authors: Yu-Hung Wang
Chien-Chin Lin
Chia-Lang Hsu
Sheng-Yu Hung
Chi-Yuan Yao
Sze-Hwei Lee
Cheng-Hong Tsai
Hsin-An Hou
Wen-Chien Chou
Hwei-Fang Tien
Publication date: 01-02-2021
Publisher: Springer Berlin Heidelberg
Keyword: Acute Myeloid Leukemia
Published in: Annals of Hematology / Issue 2/2021
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-04358-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2021

Allogeneic hematopoietic stem cell transplantation for intermediate-risk acute myeloid leukemia in the first remission: outcomes using haploidentical donors are similar to those using matched siblings

COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry

A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma

Prognostic value of 25-hydroxy vitamin D in extranodal NK/T cell lymphoma

Coincidence of autoimmune hemolytic anemia and pure red cell aplasia in a patient with CLL

Primary pulmonary diffuse large B cell lymphoma presenting as bulky bilateral lung tumors

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials